Literature DB >> 23017659

Effects of PTH on osteocyte function.

Teresita Bellido1, Vaibhav Saini, Paola Divieti Pajevic.   

Abstract

Osteocytes are ideally positioned to detect and respond to mechanical and hormonal stimuli and to coordinate the function of osteoblasts and osteoclasts. However, evidence supporting the involvement of osteocytes in specific aspects of skeletal biology has been limited mainly due to the lack of suitable experimental approaches. Few crucial advances in the field in the past several years have markedly increased our understanding of the function of osteocytes. The development of osteocytic cell lines initiated a plethora of in vitro studies that have provided insights into the unique biology of osteocytes and continue to generate novel hypotheses. Genetic approaches using promoter fragments that direct gene expression to osteocytes allowed the generation of mice with gain or loss of function of particular genes revealing their role in osteocyte function. Furthermore, evidence that Sost/sclerostin is expressed primarily in osteocytes and inhibits bone formation by osteoblasts, fueled research attempting to identify regulators of this gene as well as other osteocyte products that impact the function of osteoblasts and osteoclasts. The discovery that parathyroid hormone (PTH), a central regulator of bone homeostasis, inhibits sclerostin expression generated a cascade of studies that revealed that osteocytes are crucial target cells of the actions of PTH. This review highlights these investigations and discusses their significance for advancing our understanding of the mechanisms by which osteocytes regulate bone homeostasis and for developing therapies for bone diseases targeting osteocytes.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017659      PMCID: PMC3552098          DOI: 10.1016/j.bone.2012.09.016

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  69 in total

1.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

2.  Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation.

Authors:  Hai Qing; Laleh Ardeshirpour; Paola Divieti Pajevic; Vladimir Dusevich; Katharina Jähn; Shigeaki Kato; John Wysolmerski; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

3.  Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses.

Authors:  William F Powell; Kevin J Barry; Irena Tulum; Tatsuya Kobayashi; Stephen E Harris; F Richard Bringhurst; Paola Divieti Pajevic
Journal:  J Endocrinol       Date:  2011-01-10       Impact factor: 4.286

Review 4.  Function of osteocytes in bone.

Authors:  E M Aarden; E H Burger; P J Nijweide
Journal:  J Cell Biochem       Date:  1994-07       Impact factor: 4.429

5.  SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.

Authors:  Mikhail Semënov; Keiko Tamai; Xi He
Journal:  J Biol Chem       Date:  2005-05-20       Impact factor: 5.157

6.  Role for parathyroid hormone in mechanical responsiveness of rat bone.

Authors:  J W Chow; S Fox; C J Jagger; T J Chambers
Journal:  Am J Physiol       Date:  1998-01

7.  1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport.

Authors:  Olga I Kolek; Eric R Hines; Marci D Jones; Loren K LeSueur; Maciej A Lipko; Pawel R Kiela; James F Collins; Mark R Haussler; Fayez K Ghishan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-14       Impact factor: 4.052

8.  PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats.

Authors:  B Fermor; T M Skerry
Journal:  J Bone Miner Res       Date:  1995-12       Impact factor: 6.741

9.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more
  67 in total

1.  Engraftment and bone mass are enhanced by PTHrP 1-34 in ectopically transplanted vertebrae (vossicle model) and can be non-invasively monitored with bioluminescence and fluorescence imaging.

Authors:  Blake Eason Hildreth; Michelle M Williams; Katarzyna A Dembek; Krista M Hernon; Thomas J Rosol; Ramiro E Toribio
Journal:  Transgenic Res       Date:  2015-08-14       Impact factor: 2.788

Review 2.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

3.  MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.

Authors:  Jesus Delgado-Calle; Benjamin Hancock; Elive F Likine; Amy Y Sato; Kevin McAndrews; Carolina Sanudo; Angela Bruzzaniti; Jose A Riancho; James R Tonra; Teresita Bellido
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 4.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

5.  Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.

Authors:  Changjun Li; Weishan Wang; Liang Xie; Xianghang Luo; Xu Cao; Mei Wan
Journal:  Ann N Y Acad Sci       Date:  2015-04-02       Impact factor: 5.691

Review 6.  Role of bone-forming agents in the management of osteoporosis.

Authors:  Michael R McClung
Journal:  Aging Clin Exp Res       Date:  2021-02-16       Impact factor: 3.636

Review 7.  In Vivo Osteocyte Mechanotransduction: Recent Developments and Future Directions.

Authors:  Paige V Hinton; Susan M Rackard; Oran D Kennedy
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 8.  Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential.

Authors:  Marc N Wein; Marc Foretz; David E Fisher; Ramnik J Xavier; Henry M Kronenberg
Journal:  Trends Endocrinol Metab       Date:  2018-08-24       Impact factor: 12.015

9.  The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.

Authors:  Teruyo Nakatani; Tiffany Chen; Joshua Johnson; Jennifer J Westendorf; Nicola C Partridge
Journal:  J Bone Miner Res       Date:  2018-04-25       Impact factor: 6.741

10.  Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice.

Authors:  Amel Dudakovic; Emily T Camilleri; Scott M Riester; Christopher R Paradise; Martina Gluscevic; Thomas M O'Toole; Roman Thaler; Jared M Evans; Huihuang Yan; Malayannan Subramaniam; John R Hawse; Gary S Stein; Martin A Montecino; Meghan E McGee-Lawrence; Jennifer J Westendorf; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2016-10-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.